Gabaergic Neuron Vulnerability is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the cell type. See the content below for detailed information.
GABAergic neurons are inhibitory neurons that exhibit selective vulnerability in various neurodegenerative diseases. Their dysfunction contributes to network hyperexcitability, seizures, and cognitive impairment.
- GAD67 (GAD1): GABA synthesizing enzyme
- GAD65 (GAD2): Synaptic GABA production
- GABA transporter 1 (GAT-1): GABA reuptake
- Parvalbumin: Calcium-binding protein
- Somatostatin: Neuropeptide co-transmitter
- GABA-A receptor subunits: Synaptic inhibition
- GABA-B receptor subunits: Metabotropic signaling
- Various GABAergic populations
- Selective loss in hippocampus
- Contributing to seizure generation
- Striatal interneurons
- Cholinergic interneuron loss
- PV and SOM interneuron changes
- Metabolic demands: High firing rate maintenance
- Calcium dysregulation: PV neurons have high calcium
- Oxidative stress: Susceptible to ROS
- Protein aggregation: Selective inclusion formation
- Network hyperexcitability: Disinhibition
- Seizure predisposition: Especially in AD
- Oscillation disruption: Gamma rhythms impaired
- Cognitive dysfunction: Memory/attention deficits
- Feedforward inhibition: Disrupted
- Feedback inhibition: Impaired
- Gain control: Altered
- GABA-A modulators: Benzodiazepines (caution)
- GABA-B agonists: Baclofen
- GAD enhancement: Gene therapy approaches
- Optogenetic stimulation: PV neuron activation
- Chemogenetic approaches: Designer receptors
- Transplantation: GABAergic neuron grafts
- GABA levels in CSF
- PET of GABA receptors
- Electrophysiological markers
The study of Gabaergic Neuron Vulnerability has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Palop, J.J., et al. (2007). Aberrant excitatory network activity in Alzheimer's disease. Nature Neuroscience, 10(11), 1348-1354.
- Brady, D.R., & Mufson, E.J. (1997). Parvalbumin-immunoreactive neurons in the hippocampal formation in Alzheimer's disease. Neuroscience, 77(2), 377-387.
- Heckers, S., et al. (1991). NPY and somatostatin in Alzheimer's disease. Neuroscience Letters, 123(2), 136-139.
- Ranganath, C., & Bollich, B. (2008). A role for somatostatin interneurons in hippocampal memory. Neuron, 60(4), 553-555.
- Rudolph, U., & Möhler, H. (2013). GABA-based therapeutic approaches: GABA A receptor subtypes. Current Opinion in Pharmacology, 13(1), 90-95.